Michael Metzger's Insider Trades & SAST Disclosures
Michael Metzger's most recent trade in Syndax Pharmaceuticals Inc was a trade of 6,074 Common Stock done at an average price of $7.2 . Disclosure was reported to the exchange on March 14, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Michael Metzger.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 14 Mar 2025 | 6,074 | 306,195 (1%) | 0% | 7.2 | 43,733 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 6,074 | 0 | - | - | Stock options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 7,814 | 0 | - | - | Stock options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 04 Mar 2025 | 7,814 | 307,935 (1%) | 0% | 7.2 | 56,261 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 15.05 per share. | 04 Mar 2025 | 7,814 | 300,121 (0%) | 0% | 15.0 | 117,564 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 15.50 per share. | 10 Feb 2025 | 13,288 | 300,121 (0%) | 0% | 15.5 | 206,017 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2025 | 364,000 | 364,000 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2025 | 89,000 | 313,409 (1%) | 0% | 0 | Common Stock | |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2025 | 60,500 | 224,409 (0%) | 0% | 0 | Common Stock | |
| Pyxis Oncology Inc | Michael Metzger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2024 | 70,683 | 70,683 | - | - | Stock Option (Right to Buy) | |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 214,500 | 214,500 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Metzger Michael | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 107,250 | 124,909 (0%) | 0% | 0 | Common Stock | |
| Syndax Pharmaceuticals Inc | Metzger Michael | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 39,000 | 163,909 (0%) | 0% | 0 | Common Stock | |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2023 | 5,959 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 27.64 per share. | 06 Feb 2023 | 5,959 | 17,659 (0%) | 0% | 27.6 | 164,697 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.38 per share. | 06 Feb 2023 | 5,959 | 23,618 (0%) | 0% | 6.4 | 38,018 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 410,000 | 410,000 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2022 | 16,231 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.29 per share. | 06 Oct 2022 | 16,231 | 17,659 (0%) | 0% | 25.3 | 410,508 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.77 per share. | 06 Oct 2022 | 16,231 | 33,890 (0%) | 0% | 8.8 | 142,346 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2022 | 29,606 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.77 per share. | 30 Sep 2022 | 29,606 | 47,265 (0%) | 0% | 8.8 | 259,645 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.02 per share. | 30 Sep 2022 | 29,606 | 17,659 (0%) | 0% | 25.0 | 740,757 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.77 per share. | 30 Sep 2022 | 2,883 | 20,542 (0%) | 0% | 8.8 | 25,284 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.01 per share. | 30 Sep 2022 | 2,883 | 17,659 (0%) | 0% | 25.0 | 72,107 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2022 | 2,883 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.77 per share. | 30 Sep 2022 | 1,280 | 18,939 (0%) | 0% | 8.8 | 11,226 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.02 per share. | 30 Sep 2022 | 1,280 | 17,659 (0%) | 0% | 25.0 | 32,026 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2022 | 1,280 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 21.06 per share. | 25 Jul 2022 | 19,764 | 17,659 (0%) | 0% | 21.1 | 416,139 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jul 2022 | 19,764 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.38 per share. | 25 Jul 2022 | 19,764 | 37,423 (0%) | 0% | 6.4 | 126,094 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jul 2022 | 11,838 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 21.06 per share. | 25 Jul 2022 | 11,838 | 17,659 (0%) | 0% | 21.1 | 249,254 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.38 per share. | 25 Jul 2022 | 11,838 | 29,497 (0%) | 0% | 6.4 | 75,526 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 21.07 per share. | 06 Jul 2022 | 15,009 | 17,659 (0%) | 0% | 21.1 | 316,307 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jul 2022 | 15,009 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.38 per share. | 06 Jul 2022 | 15,009 | 32,668 (0%) | 0% | 6.4 | 95,757 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jul 2022 | 100 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 21.00 per share. | 06 Jul 2022 | 100 | 17,659 (0%) | 0% | 21 | 2,100 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.38 per share. | 06 Jul 2022 | 100 | 17,759 (0%) | 0% | 6.4 | 638 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2022 | 325,000 | 325,000 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Sale of securities on an exchange or to another person at price $ 20.29 per share. | 16 Dec 2021 | 45,000 | 17,659 (0%) | 0% | 20.3 | 912,960 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.77 per share. | 16 Dec 2021 | 45,000 | 62,659 (0%) | 0% | 8.8 | 394,650 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2021 | 45,000 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2021 | 22,715 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Sale of securities on an exchange or to another person at price $ 19.08 per share. | 16 Dec 2021 | 22,715 | 17,659 (0%) | 0% | 19.1 | 433,400 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.38 per share. | 16 Dec 2021 | 22,715 | 40,374 (0%) | 0% | 6.4 | 144,922 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Sale of securities on an exchange or to another person at price $ 20.29 per share. | 16 Dec 2021 | 16,000 | 17,659 (0%) | 0% | 20.3 | 324,608 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.38 per share. | 16 Dec 2021 | 16,000 | 33,659 (0%) | 0% | 6.4 | 102,080 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2021 | 16,000 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2021 | 1,676 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Sale of securities on an exchange or to another person at price $ 19.02 per share. | 16 Dec 2021 | 1,676 | 17,659 (0%) | 0% | 19.0 | 31,877 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.38 per share. | 16 Dec 2021 | 1,676 | 19,335 (0%) | 0% | 6.4 | 10,693 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.38 per share. | 13 Dec 2021 | 34,564 | 52,223 (0%) | 0% | 6.4 | 220,518 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Dec 2021 | 34,564 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Sale of securities on an exchange or to another person at price $ 19.05 per share. | 13 Dec 2021 | 34,564 | 17,659 (0%) | 0% | 19.1 | 658,555 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Dec 2021 | 2,045 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Sale of securities on an exchange or to another person at price $ 19.05 per share. | 13 Dec 2021 | 2,045 | 17,659 (0%) | 0% | 19.1 | 38,964 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 13 Dec 2021 | 2,045 | 19,704 (0%) | 0% | 7.2 | 14,724 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Sale of securities on an exchange or to another person at price $ 19.13 per share. | 25 Oct 2021 | 44,704 | 17,659 (0%) | 0% | 19.1 | 855,335 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 25 Oct 2021 | 44,704 | 62,363 (0%) | 0% | 7.2 | 321,869 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Oct 2021 | 44,704 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 25 Oct 2021 | 16,296 | 33,955 (0%) | 0% | 7.2 | 117,331 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Oct 2021 | 16,296 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Sale of securities on an exchange or to another person at price $ 19.20 per share. | 25 Oct 2021 | 16,296 | 17,659 (0%) | 0% | 19.2 | 312,825 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Sep 2021 | 24,437 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 27 Sep 2021 | 24,437 | 42,096 (0%) | 0% | 7.2 | 175,946 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Sale of securities on an exchange or to another person at price $ 19.51 per share. | 27 Sep 2021 | 24,437 | 17,659 (0%) | 0% | 19.5 | 476,832 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 20 Sep 2021 | 31,455 | 49,114 (0%) | 0% | 7.2 | 226,476 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Sale of securities on an exchange or to another person at price $ 19.24 per share. | 20 Sep 2021 | 31,455 | 17,659 (0%) | 0% | 19.2 | 605,046 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2021 | 31,455 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 20 Sep 2021 | 4,808 | 22,467 (0%) | 0% | 7.2 | 34,618 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Sale of securities on an exchange or to another person at price $ 19.16 per share. | 20 Sep 2021 | 4,808 | 17,659 (0%) | 0% | 19.2 | 92,108 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2021 | 4,808 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Sale of securities on an exchange or to another person at price $ 19.02 per share. | 20 Sep 2021 | 300 | 17,659 (0%) | 0% | 19.0 | 5,706 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 20 Sep 2021 | 300 | 17,959 (0%) | 0% | 7.2 | 2,160 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2021 | 300 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Sep 2021 | 44,349 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Sale of securities on an exchange or to another person at price $ 19.15 per share. | 13 Sep 2021 | 44,349 | 17,659 (0%) | 0% | 19.2 | 849,394 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 13 Sep 2021 | 44,349 | 62,008 (0%) | 0% | 7.2 | 319,313 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Sale of securities on an exchange or to another person at price $ 19.02 per share. | 13 Sep 2021 | 16,651 | 17,659 (0%) | 0% | 19.0 | 316,639 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Sep 2021 | 16,651 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 13 Sep 2021 | 16,651 | 34,310 (0%) | 0% | 7.2 | 119,887 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 160,000 | 160,000 | - | - | Stock Option (Right to Buy) | |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 15,000 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 01 Feb 2021 | 15,000 | 32,659 (0%) | 0% | 7.2 | 108,000 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Sale of securities on an exchange or to another person at price $ 20.19 per share. | 01 Feb 2021 | 15,000 | 17,659 (0%) | 0% | 20.2 | 302,799 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2020 | 15,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Sale of securities on an exchange or to another person at price $ 22.97 per share. | 01 Dec 2020 | 15,000 | 17,659 (0%) | 0% | 23.0 | 344,513 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 01 Dec 2020 | 15,000 | 32,659 (0%) | 0% | 7.2 | 108,000 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Sale of securities on an exchange or to another person at price $ 20.31 per share. | 04 Nov 2020 | 100,000 | 17,659 (0%) | 0% | 20.3 | 2,031,410 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 04 Nov 2020 | 100,000 | 117,659 (0%) | 0% | 7.2 | 720,000 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael Metzger | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2020 | 100,000 | 0 | - | - | Stock Options (Right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges